http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150103874-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6171684de68ce62ef3fbf1655618249 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2014-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7195f8bbd55d9838031d31456638ef7b |
| publicationDate | 2015-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20150103874-A |
| titleOfInvention | Use of miR-101 for NLK expression inhibitor |
| abstract | The present invention relates to the use of miR-101 as an inhibitor of the expression of NLK, and more particularly to the use of miR-101 as an inhibitor of NLK, and more particularly, to a method for inhibiting the proliferation of miR- 101 < / RTI > The present invention is the first to demonstrate that miR-101 is a regulator that inhibits the expression of NLK. MiR-101 inhibits the expression of NLK and is useful as a therapeutic method for preventing or treating liver cancer induced by overexpression of NLK And may be effectively utilized for the treatment of various diseases induced by overexpression of other NLKs. |
| priorityDate | 2014-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 285.